May 29, 2014

Sanguine and Mayo Clinic Bioservices Begin Work Together

By AJ Montpetit

Article Originally Featured on Yahoo Finance

INVENT Ventures (IDEA), a venture firm that builds, manages, and invests in early-stage web and mobile technology companies, announced today that its portfolio company Sanguine Biosciences, Inc. (“Sanguine”) has secured an agreement with Mayo Clinic Bioservices.

Under this agreement, Mayo Clinic Bioservices will process, store and ship biospecimens collected by Sanguine for the purpose of developing new therapies. Mayo Clinic Bioservices will provide integrated laboratory services including specimen accessioning, processing, nucleic acid extraction, specimen tracking, storage and shipping. Mayo Clinic Bioservices is a new service from the Mayo Clinic Center for Individualized Medicine.

"Partnering with Mayo Clinic Bioservices dramatically increases the scalability of the Sanguine's business and furthers the company in its goal of improving efficiency in the development of personalized medical research," said Bryce Knight, CEO of INVENT Ventures. "Not only does this partnership benefit Sanguine and its clients which include 20 of the top 40 pharmaceutical and biotechnology companies, but more importantly it allows patients on its waiting list to participate in the research and development of new treatments."


Click here to access the full the press release - Sanguine to begin work with Mayo Clinic Bioservices.




Tags: Bioservices, Biospecimen, Biospecimens, dna test, DNA Testing, gene sequencing, genome science, genomic medicine, genomics, IDEA, individualized medicine, Invent Ventures, mayo clinic, personal genomics, personalized medicine, predictive medicine, Sanguine, Uncategorized

Contact Us · Privacy Policy